Brady et al. used DSP to characterize metastatic prostate cancer and found that most metastases lacked immune cell infiltrates and showed a high expression of immune checkpoint proteins, such as B7-H3/CD276 and TIM317. This evidence concerns the gene CD276 and prostate carcinoma.